Quantum Genomics

EU: ALQGC

€54.1m market cap

€2.65 last close

Quantum Genomics is a biopharmaceutical company developing firibastat, a brain aminopeptidase A inhibitor for treating hypertension and heart failure. Its mechanism is implicated in the 25% of patients resistant to treatment.

Investment summary

Quantum Genomics is investigating brain aminopeptidase A inhibitors, a new class of drug, for the treatment of hypertension and heart failure. Data from the Phase IIb NEW-HOPE trial strongly suggests that firibastat is an efficacious, safe drug. After eight weeks of treatment, patients saw a statistically significant reduction from baseline (p<0.0001) in systolic blood pressure of 9.7mmHg. A pivotal Phase III in 500 resistant hypertension patients has been initiated with results in H221. The company recently initiated a Phase IIb of firibastat in 294 heart failure patients, with results expected in H220.

Y/E Dec
Revenue (€m)
EBITDA (€m)
PBT (€m)
EPS (c)
P/E (x)
P/CF (x)
2018A 0.0 (13.6) (13.6) (93.94) N/A N/A
2019A 0.0 (10.8) (10.8) (52.69) N/A N/A
2020E 0.0 (20.7) (20.7) (96.39) N/A N/A
2021E 0.0 (21.6) (21.6) (96.56) N/A N/A
Industry outlook

The angiotensin pathway is one of the primary methods of modulating blood pressure and is the target of many anti-hypertensive drugs, including ACEs and ARBs. However, there is a parallel pathway in the brain responsible for the secretion of vasopressin and heart rate that is unaddressed by current drugs and that is being targeted by Quantum Genomics.

Last updated on 11/08/2020
Sector
Healthcare
Share price graph
Balance sheet
Forecast net debt (€m) 5.2
Forecast gearing ratio (%) 84
Price performance
%
1m
3m
12m
Actual (1.5) (16.4) (46.5)
Relative* (3.1) (25.3) (43.3)
52-week high/low €5.4/€1.9
*% relative to local index
Key management
Jean-Philippe Milon CEO
Marc Karako CFO
Lionel Ségard Founder & Chairman

Content on Quantum Genomics